Innoviva, Inc.

Healthcare

NASDAQ:INVA · NASDAQ Global Select

Market Cap $1.66B Beta 0.35 P/E (TTM) 3.3

$22.49 -1.33%

-$0.30 today

52W Low $16.52High $25.15

Vol 1.40M · Avg 0.78M

EPS (TTM) $6.80Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+8.02%

Period High

$24.24

Period Low

$16.67

Latest

$22.49

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Dianthus Therapeutics, Inc.

NASDAQ:DNTH

$3.35B

Relay Therapeutics, Inc.

NASDAQ:RLAY

$2.79B

Enliven Therapeutics, Inc.

NASDAQ:ELVN

$2.74B

Syndax Pharmaceuticals, Inc.

NASDAQ:SNDX

$1.70B

Atai Beckley Inc.

NASDAQ:ATAI

$1.49B

Inhibrx Biosciences, Inc.

NASDAQ:INBX

$1.34B

Immatics N.V.

NASDAQ:IMTX

$1.30B

Nektar Therapeutics

NASDAQ:NKTR

$1.17B

CureVac N.V.

CVAC

$1.05B

MiMedx Group, Inc.

NASDAQ:MDXG

$547.38M

What is the latest INVA filing?

The latest filing shown is 4 dated May 22, 2026.

How many recent filings does INVA have?

Intrinsic Alpha currently shows 20 recent filings for INVA.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.